Quick Dispatch:
Your glp-1 cardiovascular outcome trials Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp-1 cardiovascular outcome trials Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease ships.
Need Help?
Questions about glp-1 cardiovascular outcome trials Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp-1 cardiovascular outcome trials Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease in your area.
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
29.59
SELECT Trial
26.93
GLP-1 receptor agonists were developed for glycemic control. The cardiovascular outcome data has since reframed how cardiologists need to think about this drug class entirely. Across LEADER, SUSTAIN-6, REWIND, and SELECT, GLP-1
28.71
The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action
22.44
SGLTi and GLP-1 in HF
22.94
Review of Cardiovascular Outcome Trials (CVOTs) for GLP-1 Receptor
29.91
Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR
29.20
